EHElizabeth Holt

Elizabeth Holt

*This is an algorithmically generated author record based on publicly available information.

Elizabeth Holt has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sustained reductions in hyperglycemia using a diabetes app with connected glucose meters in people with type 2 diabetes at higher risk for complications

    by Mike Grady, Stephen MacKintosh, Matthew Fryett, Elizabeth Holt

    Aim: Assess the benefits of using a diabetes app and connected blood glucose (BG) meter in people with type 2 diabetes (PwT2D) with higher-than-recommended mean BG. It is well understood that sustained higher levels of glycemia are linked to diabetes related complications and that early intervention to reduce hyperglycemia is an important clinical goal. Methods: We sourced server data from a total population of 22,696 PwT2D using the OneTouch Reveal diabetes app in conjunction with a OneTouch Verio Flex or Reflect BG meter. We identified three groups (mean BG > 180, > 155, and between > 155 and < 180 mg/dL) at higher risk for diabetes-associated complications based on their hyperglycemia. Data from their first 14 days using the app was compared with the last 14 days at the end of each timeframe, using paired within-subject differences. Results: At 1 year in PwT2D with baseline mean BG > 155 mg/dL, readings in range (RIR) improved by 24.0%, and mean BG decreased by 35.9 mg/dL, from 196.4 mg/dL to 160.5 mg/dL. These improvements were due to reductions in hyperglycemic readings. Subjects with the highest baseline mean BG of > 180 mg/dL had the greatest reduction (–54.3 mg/dL) in mean BG after experiencing the new app and meter for 1 year. Those engaging more often with the app had greater improvements in glycemia. Conclusions: In PwT2D with higher-than-recommended mean BG, substantial improvements in glycemia were associated with subjects using a diabetes app with a connected blood glucose meter at 3 months, and these improvements were sustained out to 1-year.

  • Real-World Follow-Up of People With Type 2 Diabetes Using a Mobile Diabetes App With Connected Glucose Meters Finds Improvements in Glycemia Are Durable Over 5 Years

    by Mike Grady, Stephen MacKintosh, Matthew Fryett, Stuart Phillips, Elizabeth Holt

    Objective: Evidence from long-term, real-world use of blood glucose (BG) monitoring technologies is sparse. We investigated whether using a diabetes app with connected meters could support durable diabetes management improvements in people with type 2 diabetes (T2D) over 5-years. Methods: Anonymized glucose and app analytics from 501 people with T2D were extracted from our server. The first 14 days using the app were compared with the last 14 days of each consecutive year for 5 years, using paired within-subject differences. Subjects had ≥365 BG readings per year. Results: People with T2D improved BG readings in range (RIR, 70-180 mg/dL) by +6.9 percentage points (%pts, 74.6% to 81.5%) and readings in tight range (RITR, 70-140 mg/dL) by +7.8%pts (49.2% to 57.0%) at year 1. Year 1 improvements in RIR and RITR remained evident at year 5 (+7.5%pts and +7.7%pts, respectively). Reductions in hyperglycemic readings (>180 and >250 mg/dL) explained the improvements in RIR and RITR over the 5-years. Mean BG reduced by -9.1 mg/dL at year 1 (150.2 to 141.1 mg/dL) and this was sustained at year 5 (-10.6 mg/dL, 150.2 to 139.6 mg/dL). Subjects performed BG checks at a consistent level, equivalent to 1.8 to 2.1 checks per day, over 5 years. All these glycemic changes were significant (p4 app sessions per week) effected better diabetes management. Conclusion: Real-world follow-up of people with type 2 diabetes using a diabetes app with connected meters found improvements in glycemia were durable over 5-years.


  • Open Access

    Older Age Is No Barrier to Improvements in Glycemia in People with Diabetes When Using a Diabetes App with a Bluetooth® Connected Blood Glucose Meter

    by Elizabeth Holt, Stuart Philips, Mike Grady

    Background: Real-world evidence on technology use by older people with diabetes (PWDs) is sparse. We show that using the OneTouch Reveal® (OTR) diabetes app with Bluetooth® connected blood glucose meters improves diabetes management in older PWDs. Methods: Anonymized glucose and app analytics from 160,545 PWDs, including 63,621 PWDs ≥65 years, were extracted from our server. Data from their first 14 days using the OTR app was compared with 14 days prior to a 180-day timepoint using paired within-subject differences. Results: Data was retrieved from 133,817 people with type 2 diabetes (PwT2D; 78,167 <65 years and 55,650 ≥65 years) and 26,728 people with type 1 diabetes (PwT1D; 18,757 <65 years and 7971 ≥65 years). PwT2D ≥65 years improved blood glucose readings in range (RIR, 70-180mg/dL) at 180-days by +9.3 percentage points (%pts, 72.0 to 81.3%) and PwT1D improved by +5.2 %pts (60.6 to 65.9%). RIR progressively improved with higher app engagement in PwT2D ≥65 years, ranging from +7.2 %pts in those performing 10 sessions per week. RIR also progressively improved in PwT1D ≥65 years from +1.3 %pts with 10 sessions per week. These glycemic changes were statistically significant (p < 0.001). The proportion of hypoglycemic readings remained largely unchanged. Conclusions: Sustained improvements in glycemia showed progressive gains with stronger engagement with a diabetes app in PWDs ≥65 years, giving credence to the view that age is no barrier when using diabetes technology.


  • Open Access

    Dynamic Interference Testing—Unexpected Results Obtained with the Abbott Libre 2 and Dexcom G6 Continuous Glucose Monitoring Devices

    by Hendrick Jensch, Steven Setford, Nicole Thomé, Geethan Srikanthamoorthy, Lea Weingärtner, Mike Grady, Elizabeth Holt, Andreas Pfützner

    Background: Sensors for continuous glucose monitoring (CGM) are now commonly used by people with type 1 and type 2 diabetes. However, the response of these devices to potentially interfering nutritional, pharmaceutical, or endogenous substances is barely explored. We previously developed an in vitro test method for continuous and dynamic CGM interference testing and herein explore the sensitivity of the Abbott Libre2 (L2) and Dexcom G6 (G6) sensors to a panel of 68 individual substances. Methods: In each interference experiment, L2 and G6 sensors were exposed in triplicate to substance gradients from zero to supraphysiological concentrations at a stable glucose concentration of 200 mg/dL. YSI Stat 2300 Plus was used as the glucose reference method. Interference was presumed if the CGM sensors showed a mean bias of at least ±10% from baseline with a tested substance at any given substance concentration. Results: Both L2 and G6 sensors showed interference with the following substances: dithiothreitol (maximal bias from baseline: L2/G6: +46%/−18%), galactose (>+100%/+17%), mannose (>+100%/+20%), and N-acetyl-cysteine (+11%/+18%). The following substances were found to interfere with L2 sensors only: ascorbic acid (+48%), ibuprofen (+14%), icodextrin (+10%), methyldopa (+16%), red wine (+12%), and xylose (>+100%). On the other hand, the following substances were found to interfere with G6 sensors only: acetaminophen (>+100%), ethyl alcohol (+12%), gentisic acid (+18%), hydroxyurea (>+100%), l-cysteine (−25%), l-Dopa (+11%), and uric acid (+33%). Additionally, G6 sensors could subsequently not be calibrated for use after exposure to dithiothreitol, gentisic acid, l-cysteine, and mesalazine (sensor fouling). Conclusions: Our standardized dynamic interference testing protocol identified several nutritional, pharmaceutical and endogenous substances that substantially influenced L2 and G6 sensor signals. Clinical trials are now necessary to investigate whether our findings are of relevance during routine care.


  • Open Access

    Improved glycemic outcomes in people with type 2 diabetes using smart blood glucose monitoring integrated with popular digital health therapeutics

    by Mike Grady, Elizabeth Holt, Hilary Cameron, Steven Edelman

    The increasing prevalence of metabolic syndrome and type 2 diabetes places a burden on healthcare systems, necessitating cost-effective, engaging and accessible interventions to address the underlying behavioral and lifestyle drivers. Our study evaluated combining Bluetooth connected OneTouch blood glucose meters (BGM) and the OneTouch Reveal mobile app with one of four digital therapeutic apps. Each group was independent, with people with type 2 diabetes (PwT2D) themselves choosing their therapeutic intervention, to better reflect real-world use. Our 3-month decentralized study screened 912 subjects, with 612 returning mail-in A1cs, providing 191 subjects (Noom = 68, Fitbit = 31, Cecelia Health = 47, Welldoc = 45) who met all inclusion criteria, including entry A1c 7.5 to 12.0%. The primary endpoint of A1c change showed improvement in the overall group by − 0.77% (95% CI − 0.98 to − 0.56, n = 141) after 3-months, Noom − 1.03% (CI − 1.4 to − 0.61, n = 49), Fitbit − 0.56% (CI − 1.0 to − 0.11, n = 24), Cecelia Health − 0.76% (CI − 1.2 to − 0.36, n = 36), Welldoc − 0.55% (CI − 0.94 to − 0.17, n = 32). In terms of secondary endpoints, more than half (56%) of these PwT2D lowered A1c by ≥ 0.5% and more than a third (36%) lowered A1c by ≥ 1.0%, with similar improvements across each of the four independent groups. Our real-world approach shows the potential for connected BGMs and widely accessible digital therapeutics to contribute to improvements in glycemic outcomes.


  • Open Access

    Glycemic trends, app engagement and achievement of gestational diabetes guideline targets using a diabetes app and Bluetooth® connected blood glucose meters

    by Mike Grady, Hilary Cameron, Elizabeth Holt

    Aim: Current diabetes guidelines recommend people with gestational diabetes mellitus (PwGDM) use primarily blood glucose meters (BGM) for diabetes management. We evaluated glycemic trends and guideline-recommended glycemic targets achieved in PwGDM using a diabetes app with a family of Bluetooth® connected BGMs. Methods: Anonymized glucose and app analytics data from 26,382 PwGDM were sourced from a server. Data from their first 7-days using the app with connected BGMs was compared to 7-days prior to a 10-week timepoint. Results: Percent fasting readings in range (RIR, < 5.3 mmol/L) improved by +20.3 percentage points in the overall population. Improved glucose RIR (3.5 to 7.8 mmol/L) (+8.3 percentage points), mean blood glucose (BG, –0.59 mmol/L), and fasting RIR (+33.2 percentage points) were observed in those with baseline mean BG ≥ 6.1 mmol/L. Improvements in mean BG of –0.32 to –2.36 mmol/L, and RIR of +3.0 to +38.3 percentage points correlated with higher baseline mean BG ≥ 6.1 to ≥ 7.8 mmol/L. Only 58.5% of PwGDM with baseline mean BG ≥ 6.1 mmol/L had > 80% RIR at baseline, which improved to 79.5% at 10 weeks. PwGDM averaged 17 app sessions and 90 minutes per week on the app. Conclusions: PwGDM engaged with the diabetes app and connected BGM, facilitating attainment of glycemic targets, an especially important outcome for those with higher mean glucose at baseline.

  • Open Access

    Sustained Improvements in Readings in-Range Using an Advanced Bluetooth® Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence from more than 55,000 People with Diabetes

    by Mike Grady, Hilary Cameron, Elizabeth Holt

    Introduction The OneTouch Verio Reflect® (OTVR) Blood Glucose Meter features a color range indicator and provides on-meter guidance, insights, and encouragement. Diabetes management is enhanced by the OneTouch Reveal® (OTR) Mobile App. We sought to provide real-world evidence (RWE) that combining devices improves glycemia. Methods Anonymized glucose and app analytics from more than 55,000 people with diabetes (PWDs) were extracted from a server. Data from their first 14 days using OTVR Meter and OTR App was compared with 14 days prior to 90- and 180-day timepoints using paired within-subject differences. Results In people with type 1 (PwT1D) or type 2 diabetes (PwT2D), readings in-range (RIR 70–180 mg/dL) improved by 7.8 percentage points (57.9–65.7%) and 12.0 percentage points (72.8–84.8%), respectively, over 180 days and hyperglycemia (> 180 mg/dL) was reduced by − 8.4 percentage points (37.9–29.5%) and − 12.2 percentage points (26.2–14.1%). RIR improved by > 10 percentage points in 38% of PwT1D and 39% of PwT2D. PwT1D spending > 2 to 4 sessions or > 10 to 20 min per week on the app improved RIR by 7.0 and 8.2 percentage points, respectively. PwT2D spending > 2 to 4 sessions or > 10 to 20 min per week on the app improved RIR by 12.6 and 12.1 percentage points, respectively. In PwT1D or T2D, mean blood glucose reduced by − 14.3 and − 19.8 mg/dL, respectively, from baseline to 180 days, with no clinically meaningful changes in percentage of hypoglycemic readings (< 70 mg/dL). PwT1D 65 years and older performed the most app sessions (10 per week) and improved RIR by 7.9 percentage points. PwT2D 65 years and older spent more time on the app (45 min per week) than PwT2D of any other age and improved RIR by 7.6 percentage points. All glycemic changes were statistically significant (p < 0.0005). Conclusion Real-world data from more than 55,000 PWDs demonstrates sustained improvements in readings in-range in PWDs using the OneTouch Verio Reflect Blood Glucose Meter and OneTouch Reveal App.


  • Open Access

    Improved Glycemic Control Using a Bluetooth®-Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence From Over 144 000 People With Diabetes

    by Mike Grady, Hilary Cameron, Elizabeth Holt

    Background: The OneTouch Verio Flex® (OTVF) blood glucose (BG) meter features a ColorSure® Range Indicator. Diabetes management is enhanced by connecting the meter to the OneTouch Reveal® (OTR) mobile app. We sought to provide real-world evidence (RWE) that combining both devices improves glycemic control. Methods: Anonymized glucose and app analytics were extracted from a server from over 144 000 people with diabetes (PWDs). Data from their first 14 days using OTVF and OTR were compared with 14 days prior to 90- and 180-day timepoints using paired within-subject differences. Results: In people with type 1 diabetes (PwT1D) or people with type 2 diabetes (PwT2D), readings in-range (RIR) improved by +6.1 (54.5% to 60.6%) and +11.9 percentage points (68.2% to 80.1%), respectively, over 180 days, and hyperglycemia was reduced by −6.6 (40.5% to 33.9%) and −12.0 (30.3% to 18.3%). In total, 35% of PwT1D and 40% of PwT2D improved RIR by >10 percentage points. People with type 1 diabetes spending two to four sessions or 10 to 20 minutes per week on the app improved RIR by +5.1 and 7.0, respectively. People with type 2 diabetes spending two to four sessions or 10 to 20 minutes per week on the app improved RIR by +11.6 and 12.0, respectively. In PwT1D or PwT2D, mean BG reduced by −11.4 and −19.5 mg/dL, respectively, from baseline to 180 days, with no clinically meaningful changes in percentage of hypoglycemic readings. All glycemic changes were statistically significant ( P < .0005 level). Conclusion: Real-world data from over 144 000 PWDs demonstrated improved percentage readings in-range and reduced hyperglycemia in PWDs using the OneTouch Verio Flex blood glucose meter and OneTouch Reveal app.


  • Open Access

    Real-World Evidence of Improved Glycemic Control in People with Diabetes Using a Bluetooth-Connected Blood Glucose Meter with a Mobile Diabetes Management App

    by Mike Grady, Hilary Cameron, Amey Bhatiker, Elizabeth Holt, Oliver Schnell

    Background: The OneTouch Verio Reflect (OTVR) meter provides ColorSure Dynamic Range Indicator (DCRI) and Blood Sugar Mentor (BSM) features that are complemented by the OneTouch Reveal (OTR) mobile app. We sought to provide real-world evidence that these products support improved glycemic control. Methods: Anonymised glucose and app analytics were extracted from the LifeScan server for 4154 people with type 1 diabetes (PwT1D) and 13,623 people with type 2 diabetes (PwT2D). Data from their first 14 days were compared with the 14 days before the 90-day time point using paired within-subject differences. Results: Percentage glucose readings in range (RIR) 70–180 mg/dL improved by +8.1% (from 58% to 66.1%) in PwT1D and by +11.2% (from 72.4% to 83.6%) in PwT2D. Hyperglycemic readings (>180 mg/dL) reduced by −8.5% (from 37.1% to 28.6%) in PwT1D and by −11.3% (from 26.4% to 15.1%) in PwT2D. Mean glucose reduced on average by −14.5 mg/dL (from 174.8 to 160.2 mg/dL) in PwT1D and −18.2 mg/dL (from 157.8 to 139.6 mg/dL) in PwT2D. Glycemic improvement was strongly associated with OTR app engagement. Two to three sessions or 11 to 20 min/week in the app improved readings in range in PwT1D by +7.0% or +8.4%, respectively. Similar engagement trends for glycemic improvement were observed in PwT2D. Proportions of subjects achieving a 5% or 10% improvement in RIR were 46.9%/36.6% for PwT1D and 48.7%/37.7% for PwT2D. Conclusions: Real-world data from over 17,000 people with diabetes (PWDs) demonstrated significantly improved readings in range and reduced the burden of hyperglycemia in PWDs using the OTVR meter and OTR app.